Avacta Group Plc (AIM:AVCT)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 333.61M |
| Revenue (ttm) | 113.00K |
| Net Income (ttm) | -62.60M |
| Shares Out | 453.28M |
| EPS (ttm) | -0.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,667,227 |
| Average Volume | 2,351,020 |
| Open | 75.50 |
| Previous Close | 74.30 |
| Day's Range | 73.77 - 77.00 |
| 52-Week Range | 26.00 - 84.00 |
| Beta | -0.16 |
| RSI | 54.04 |
| Earnings Date | May 1, 2026 |
About Avacta Group
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that driv... [Read more]
Financial Performance
In 2024, Avacta Group's revenue was 113,000, a decrease of -96.04% compared to the previous year's 2.85 million. Losses were -52.84 million, 58.9% more than in 2023.
Financial StatementsNews
Avacta Group Transcript: Study Update
Phase 1B data for AVA6000 in salivary gland cancer show a 90% disease control rate, strong safety profile, and effective tumor targeting even in low-FAP patients. Ongoing enrollment and survival data will inform a randomized Phase 2/3 trial.
Avacta Group Transcript: Status Update
The dual-payload pre|CISION platform enables targeted, simultaneous delivery of two drugs to tumors, overcoming resistance and reducing toxicity. Clinical progress continues with AVA6103 on track for a 2026 trial, a strengthened IP portfolio, and a cash runway into late 2026 supporting multiple upcoming catalysts.
Avacta Group Earnings Call Transcript: H1 2025
Interim results highlight strong progress in clinical and preclinical oncology programs, with AVA6000 and AVA6103 advancing on schedule. Financial position is stable with a cash runway into Q1 2026, and strategic partnerships are prioritized to support future development.
Avacta Group Transcript: AGM 2025
The AGM highlighted significant progress in clinical programs, strengthened leadership, and ongoing strategic partnerships. Financial challenges from the Heights Convertible Bond remain a key focus, with cash management and upcoming data catalysts expected to drive future growth.
Avacta Group Earnings Call Transcript: H2 2024
Transitioned to a pure-play oncology biotech, advancing FAPDOX and FAP-Exatecan with strong clinical and preclinical progress. Financial runway extends into Q1 2026, with additional funding and partnerships actively pursued. Key data catalysts expected in late 2025 and 2026.
Avacta Group Transcript: Status Update
AVA6000 continues to show a strong safety profile and high disease control in salivary gland cancer, with expansion cohort data expected later this year. AVA6103 demonstrated potent preclinical efficacy and is on track for clinical trials early next year, supported by AI-driven patient selection and a robust translational strategy.
Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives
AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple ...
Avacta Group Earnings Call Transcript: H1 2024
Interim results met expectations, with diagnostics turning EBITDA positive and therapeutics advancing AVA-6000 toward phase II. Divestment of diagnostics and a dual Nasdaq listing are underway to support a focused therapeutics strategy.
Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors
Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life scien...
Avacta Group Transcript: AGM 2024
The meeting highlighted a renewed focus on novel therapeutics, board and management changes, and a robust clinical pipeline led by AVA6000. Key milestones for 2024 include expansion cohort initiation, updated clinical data, and a pipeline update, with ongoing efforts to secure strategic funding.
Avacta Group Transcript: Status Update
FAP-targeted peptide drug conjugates and Affimer technology enable precise, tumor-specific delivery of potent therapeutics, with AVA-6000 showing strong clinical proof of concept and a favorable safety profile. Expansion cohorts and pipeline updates are planned for the second half of 2024.